Cardiovascular, hemodynamic, neuroendocrine, and inflammatory markers in women with and without vasomotor symptoms by Gordon, Jennifer L. et al.
Cardiovascular, hemodynamic, neuroendocrine, and 
inflammatory markers in women with and without vasomotor 
symptoms
Jennifer L. Gordon, PhD1, David R. Rubinow, MD1, Rebecca C. Thurston, PhD2, Julia 
Paulson, BS1, Peter J. Schmidt, MD3, and Susan S. Girdler, PhD1,*
1Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, 
United States
2Departments of Psychiatry, Epidemiology and Psychology, University of Pittsburgh, Pittsburgh, 
PA 15213
3Section on Behavioral Endocrinology, National Institute of Mental Health, Department of Health 
and Human Services, Bethesda, MD 20892
Abstract
Objective—Vasomotor symptoms (VMS) may be associated with an increased risk of 
cardiovascular disease. One candidate mechanism may involve alterations in physiological 
responses to stress. The current study therefore examined the relationship between self-reported 
VMS bother and cardiovascular, hemodynamic, neuroendocrine and inflammatory responses to an 
acute psychosocial stress protocol.
Methods—One hundred and eighty-six women in the menopause transition or early 
postmenopause (age 45-60) provided the data for this report. Subjective hot flash and night sweat 
bother was assessed using the Greene Climacteric Scale. Women also underwent a stressor battery 
involving a speech and a mental arithmetic task while cardiovascular, hemodynamic, 
neuroendocrine and inflammatory responses were assessed. Repeated measures regression 
analyses were used to examine the relationship between self-reported VMS and physiologic 
responses to the stressor.
Results—In multivariate analyses adjusting for potential confounders, self-reported hot flash 
bother was associated with lower overall cardiac index and stroke volume index and higher overall 
vascular resistance index and levels of the inflammatory cytokine interleukin-6. Hot flash bother 
also tended to be associated with higher overall cortisol levels and higher baseline levels of plasma 
norepinephrine. Night sweat bother, on the other hand, was associated with higher overall cortisol 
levels and tended to be associated with higher interleukin-6.
Conclusion—Self-reported VMS bother is associated with an unfavorable hemodynamic and 
neuroendocrine profile characterized by increased hypothalamic-pituitary-adrenal axis and central 
sympathetic activation, inflammation and vasoconstriction. Further research investigating this 
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profile in relation to VMS, as well as the potential health implications of this association, are 
warranted.
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vasomotor symptoms; hot flashes; hot flushes; night sweats; stress reactivity; hemodynamics; 
catecholamines; cortisol; inflammation; Trier Social Stress Test
Vasomotor symptoms (VMS) are estimated to affect up to 70% of women in the early 
menopausal years1 and are associated with impaired sleep, cognitive decline and overall 
decreased quality of life (see 2 for review). Although findings are not entirely consistent, 
with one study finding VMS to be associated with a decreased risk of cardiovascular disease 
mortality3, several recent studies suggest that VMS frequency and/or severity may be 
positively associated with cardiovascular disease risk. In one 14-year longitudinal study of 
over 11,000 women aged 45-50, women who reported having VMS ‘often’ had a two-fold 
increased risk of developing coronary heart disease (CHD) over the course of the study when 
compared to women who reported no VMS4. Furthermore, the Women's Health Initiative 
Observational Study (WHIOS), involving approximately 60,000 postmenopausal women 
aged 50 to 79 who were followed for an average of 9.7 years,5 found that VMS, particularly 
late-onset VMS, were associated with an increased risk of major CHD, stroke and total 
cardiovascular disease (HRs = 1.30-1.46). A third study of over 10,000 Dutch and Swedish 
women aged 46-64 followed for a mean of 10 years, night sweats, but not hot flashes, were 
associated with a moderately increased risk of CHD (HR = 1.33)6.
VMS have also been associated with multiple cardiovascular disease precursors, including 
indices of subclinical cardiovascular disease. In an ancillary study of the Study of Women's 
Health Across the Nation (SWAN) including 492 women aged 45-58, hot flashes were 
associated with reduced flow-mediated dilation, increased coronary artery and aortic 
calcification7 and higher carotid intima media thickness8. A second cohort of 302 women 
participating in the Healthy Women Study, a longitudinal study initiated in 1983, found that 
women reporting a longer history of hot flashes exhibited increased aortic calcification9. 
Others have obtained similar findings10, 11, though null findings have also been reported12. 
Additionally, VMS have been associated with other CVD risk factors, including increased 
body mass index, hypertension, elevated LDL cholesterol and triglycerides (see 13 for 
review), indicators of insulin resistance 14 and diabetes15.
The mechanisms linking VMS with a potentially increased cardiovascular risk profile are 
poorly understood. However, a small body of recent research investigating the physiology of 
hot flashes suggests that disturbances in the autonomic nervous system (ANS) and 
hypothalamic-pituitary-adrenal (HPA) axis may represent a common link between VMS and 
cardiovascular disease. High frequency heart rate variability, considered an index of cardiac 
vagal control, has been found to decrease significantly during hot flashes16-18 while low 
frequency heart rate variability, in part reflecting sympathetic activation, may be higher 
during hot flashes18, 19. Some evidence indicating that compounds increasing central 
sympathetic activation (e.g., yohimbine) may provoke hot flashes while compounds 
reducing sympathetic activation (e.g., clonidine) ameliorate them20 also seem to implicate 
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the ANS in the etiology of VMS. Though the link between VMS and the HPA axis is much 
less established, one study suggests that hot flashes are followed by a temporary increase in 
cortisol21.
Indicators of altered ANS and HPA axis regulation are, in turn, associated with 
cardiovascular disease and its precursors. For example, exaggerated cardiovascular 
responses to acute mental stress22, 23 have been shown to be associated with the 
development of hypertension, subclinical atherosclerosis and cardiovascular events 
themselves14, 15. Though less well-studied, some evidence also suggests that cortisol 
responses to acute mental stress are associated with coronary artery calcification24. Repeated 
exposure to elevated cortisol levels may also, over time, render individuals resistant to the 
anti-inflammatory effects of glucocorticoids, resulting in overall increased inflammation25, 
which is itself a risk factor for cardiovascular disease26. In addition, the relative contribution 
that the myocardium versus the vasculature makes to blood pressure (BP) levels, which is 
regulated by the ANS and sympathoadrenal medullary system, has been shown to be 
associated with CVD development27. More specifically, a hemodynamic stress profile 
characterized by less cardiac output and greater relative vasoconstriction has been observed 
in groups at increased risk for CVD 28-31. Thus, to the extent that ANS and HPA axis 
disturbances are positively associated with both VMS and CVD risk, such disturbances may 
represent a common link between VMS and CVD.
The current study examined the relationship between self-reported VMS and cardiovascular, 
hemodynamic, endocrine and inflammatory responses at rest and during a well-validated 
acute mental stress task, the Trier Social Stress Test (TSST) in peri- and early 
postmenopausal women. This work may shed light on potential stress-responsive 
cardiovascular and neuroendocrine mechanisms linking VMS and CVD.
Methods
Study Overview
The current manuscript describes the results of a cross-sectional analysis of the pre-
randomization data collected as part of the Perimenopausal Estrogen Replacement Therapy 
(PERT) Study, a 12-month placebo-controlled randomized trial evaluating the mood and 
cardiovascular benefits of transdermal estradiol in perimenopausal and early postmenopausal 
women.
Participants first underwent an enrollment visit during which their study eligibility was 
assessed and informed written consent was obtained. At this time, participants completed 
questionnaires pertaining to their demographic characteristics, medical history and current 
menopausal symptoms. One month following the enrollment session, those women who 
were determined to be eligible for the randomized controlled trial (RCT) completed the first 
laboratory stress testing session, which included the Trier Social Stress Test (TSST), during 
which multiple measures of cardiovascular and endocrine reactivity were assessed. 
Participants were subsequently randomized to receive transdermal estradiol (0.1 mg) and 
micronized progesterone pills (200 mg/day) or a placebo patch and placebo pills. However, 
the data included in this report constitutes only the measures collected pre-randomization.
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Participants
186 participants included in this report (see Table 1 for participant characteristics) were 
recruited from the community to participate in the PERT Study. Women were recruited who 
were aged 45-60 years, medically healthy and perimenopausal or early postmenopausal 
according to the Stages of Reproductive Aging Workshop (STRAW+10) criteria (early 
perimenopause, defined as menstrual cycle length 7+ days longer than usual in combination 
with hot flashes; late perimenopause, defined as ≥ 2 skipped cycles and an interval of 
amenorrhea ≥60 days but within one year of the last menstrual period; and early 
postmenopause defined as an interval of amenorrhea between one and two years). Women 
who had their uterus removed (at least one ovary retained) for whom menstrual bleeding 
patterns could not be assessed were included in the study if: 1) they were experiencing VMS 
and their baseline estradiol levels were above postmenopausal concentrations (> 40 pg/ml) 
(n=17) or, 2) they were not experiencing VMS but had baseline estradiol > 40 pg/ml and 
baseline FSH levels > 14 IU/l (n=4) (a cutoff of two standard deviations above the mean 
level obtained from a sample of premenopausal women, consistent with STRAW 
guidelines)32.
Exclusion criteria included the following: current psychiatric diagnosis of major depressive 
disorder or any other current psychiatric diagnosis with severity greater than mild, a Center 
for Epidemiological Studies Depression Scale (CES-D) score > 16, a history of severe 
substance use within the past 10 years, a history of suicide attempts, use of psychotropic 
medication, hormonal preparations, or herbal compounds indicated for menopausal 
symptoms (e.g. Black Cohosh) or mood (e.g. St. John's Wort), use of statins or 
antihypertensive agents other than diuretics, regular over-the-counter medication use (e.g., 
non-steroidal anti-inflammatory agents), blood pressure >160/90 mmHg or any history of 
CVD. Multiple exclusion criteria aimed at minimizing risk related to hormone therapy also 
applied and included the following: smoking > 10 cigarettes/day, endometrial hyperplasia, 
abnormal uterine anatomy, history of thrombophlebitis or thromboembolic disorders, history 
of estrogen-dependent neoplasias, body mass index > 35. To be eligible for the study, 
women also must have had a normal mammogram within one year of study enrollment. The 
study protocol was approved by the UNC Chapel Hill Institutional Review Board. All 
participants provided informed, written consent prior to participating and received up to 
$1525 in compensation for participating in the full 12 month RCT.
Measures
Vasomotor Symptoms (VMS)—VMS were measured during the enrollment session 
using the Greene Climacteric Scale (GCS), a self-report form that asks participants to rate 
the extent to which they are currently bothered by 21 menopausal symptoms on a 4-point 
scale from ‘not at all’ to ‘extremely,’ Two of these items included “hot flushes” and 
“sweating at night,” which were used to respectively assess hot flashes and night sweats in 
the current study.
Potential Confounders—All potential confounding variables were assessed at the 
enrollment session. Race was assessed by self-report and included the following possible 
categories from which the participant could choose: White, African American, Native 
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Hawaiian or Pacific Islander, Native American, Alaska Native, Black of Caribbean, Cuban, 
European or other descent and Asian. Body mass index was calculated using researcher-
assessed height and weight measurements. Light, moderate and vigorous physical activity 
were assessed using the International Physical Activity Questionnaire (IPAQ)- short form33, 
which provides examples of commonly-performed activities at all intensities of physical 
activity and collects information on the duration (time spent) and frequency (number of 
days) engaged in activities lasting longer than 10 minutes over the course of the week to 
calculate the amount of Metabolic Equivalents (METs)-minutes associated with each 
physical activity level of intensity. To assess smoking, participants completed a 
questionnaire asking “Do you smoke?” and “If yes, approximately, how many cigarettes do 
you smoke in a day?” Categories included 5 or less, 6-10, 11-15, 16-20, 20+. Average 
number of hours of sleep per night, assessed using one item from an abbreviated version of 
the St. Mary's Hospital Sleep Questionnaire (SMHSQ)34, was used as an indicator of sleep. 
Average number of self-reported cups of caffeinated beverages consumed per day was used 
as an index of caffeine intake. Average number of self-reported alcoholic beverages 
consumed per week provided an index of alcohol intake. Menopause status was categorized 
as postmenopausal or perimenopausal based upon self-reported menstrual cycle information. 
Postmenopausal status required at least one year of amenorrhea. All other participants were 
classified as perimenopausal, including hysterectomized women meeting the estradiol and/or 
FSH study eligibility criteria. Psychological symptoms were assessed using the 
psychological subscale of the GCS, which consists of 11 items – 5 relating to depression and 
6 relating to anxiety.
Laboratory Testing
The sequence of laboratory events were as follows: 1) Instrumentation and intravenous set-
up; 2) recovery from venipuncture (20 min); 3) baseline (10 min quiet rest); 4) Trier social 
stress test (TSST) (15 min); 5) recovery (60 min). These events are described below.
All laboratory sessions began at 1:00 p.m. Upon arrival, participants were instrumented with 
a blood pressure cuff and an electrocardiogram for later monitoring of cardiovascular stress 
reactivity. A catheter was then placed into a forearm vein, to be used for blood draws using a 
non-heparinized, multi-stop-cock system allowing for blood samples to be taken at precise 
time intervals throughout testing. A curtain was drawn to prevent the participant from 
viewing the catheter and the blood draws during the stress protocol. Thirty minutes of quiet 
rest followed the i.v. setup, the first 20 min being recovery from venipuncture and minutes 
21 - 30 constituting baseline. Blood pressure and heart rate were taken at minutes 21, 23, 25, 
27 and 29 and averaged to yield a mean baseline value. Blood was sampled at minute 30 for 
baseline cortisol, IL-6, epinephrine, norepinephrine and estradiol concentrations.
The Trier Social Stress Test (TSST)
The TSST, which has been shown to induce a reliable stress response35, involved four 
components: 1) Pre-task instructions (1 minute) during which participants were introduced 
to the committee who later listened to their job talk and were given instructions for the 
mental arithmetic task; 2) Speech preparation period (5 minutes) during which time 
participants prepared a job talk for which they were to assume the role of a job candidate for 
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their “ideal job” while the selection committee stood in the room; 3) Job speech (5 minutes 
immediately following the preparation period), during which the participant delivered her 
job talk aimed at persuading the committee that she is the perfect candidate. If the 
participant ended her talk before 5 minutes, the selection committee questioned the 
participant in a systematic fashion to ensure the participant would speak the entire 5 
minutes. 4) Serial subtraction task, which involved subtracting a 1-digit number from a 4-
digit number as fast and as accurately as possible for 5 minutes. For each mistake, the 
participant was instructed by a member of the selection committee to restart from the 
beginning. Participants were video-recorded throughout their performance.
Following the arithmetic task, participants were asked to rate on a scale from 0 to 10 the 
extent to which the job speech and the arithmetic task caused them anxiety, fear, anger/ 
hostility and feelings of rejection. Using a similar scale, participants also rated how difficult 
the tasks were and how much effort they exerted in completing the tasks. Participants then 
sat quietly while watching a 60-minute travel documentary specifically chosen to include 
only mundane footage.
Blood pressure and heart rate were obtained at minutes 1, 3 and 5 of the speech preparation 
period, the job speech and the arithmetic task and at minutes 2, 4, 8, 10, 13, 16, 20, 25, 30, 
40, 45, 56 and 60 of the recovery period. These measures were then averaged to obtain a 
mean preparation, speech task, arithmetic task and recovery value for each measure. Plasma 
epinephrine and norepinephrine were sampled at minute 1 of the job speech and at minute 1 
of the arithmetic task since catecholamines peak within the first two minutes of mental 
stress36. Plasma cortisol and IL-6 was measured 10, 20, 30, 45 and 60 minutes following the 
end of the TSST to capture the delayed HPA and IL-6 responses to mental stress37-39.
Physiological Recording Procedures
The SunTech Exercise blood pressure monitor, Model 4240 (SunTech Medical Instruments, 
Inc., Raleigh, NC) provided blood pressure measurements during baseline and mental stress 
testing. Five standard stethoscopic and automated blood pressure measurements were taken 
simultaneously to ensure correct microphone placement and cuff position.
Impedance cardiography was used to noninvasively monitor cardiovascular activity40, 
including cardiac output, stroke volume, total peripheral resistance and heart rate. A custom-
designed impedance cardiograph (HIC-100 Bioimpedance Technology, Inc., Model 100, 
Chapel Hill, NC, USA) was used in conjunction with a tetrapolar band electrode 
configuration to record impedance dZ/dt and Zo signals. Impedance and electrocardiogram 
signals were processed online by specialized computer software (BIT, Chapel Hill, NC) with 
subsequent manual editing to improve accuracy. For each minute of interest, a 30 second 
continuous sample of waveforms (obtained concurrently with blood pressure) was processed 
to generate an ensemble-averaged cardiac cycle, from which SV was determined using the 
Kubicek et al. (1966)41 equation and heart rate was determined using the mean interbeat 
interval. Cardiac output and total peripheral resistance for these same minutes were then 
calculated using standard formulae40. Cardiac output, stroke volume and total peripheral 
resistance were adjusted for individual variations in body size by using body surface areas to 
derive cardiac index, stroke volume index and vascular resistance index.
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Hormone and Neuroendocrine Assays
Plasma cortisol levels were measured using a competitive coated tube radioimmunoassay 
(RIA) kit and protocol, commercially available from MP Biomedicals, Orangeburg, NY. The 
sensitivity of the assay is .07 ug/dL with intra- and inter- assay variations of 4.7% and 7.6%, 
respectively.
Plasma IL-6 levels were determined using a high-sensitivity ELISA assay kit and protocol 
from R&D Systems, Minneapolis, MN. The sensitivity of the assay is .039 pg/ml with a 
standard range of .156 to 10 pg/ml with intra- and inter- assay variations of 7.8% and 7.2%, 
respectively.
Plasma epinephrine and norepinephrine concentrations were determined (Labcorp) using an 
isocratic high performance liquid chromatography (HPLC) system and an electrochemical 
detector from Chromsystems, Germany. The lower limit of quantification for both 
compounds is 15 ng/l. Intra-assay and the intra-assay and inter- day coefficients of variation 
are <11% and <13%, respectively.
Statistical Analyses
Sensitivity analyses were used to identify extreme outliers prior to data analysis, defined as 
values 3 or more interquartile ranges below the first quartile or above the third quartile (SAS 
Institute Inc., 2011). This resulted in IL-6 data being removed for three participants, cardiac 
index data being removed for one participant, stroke volume index being removed for one 
participant, norepinephrine data being removed for one participant and epinephrine data 
being removed for four participants. While blood pressure and heart rate were normally 
distributed, cardiac index, vascular resistance index, stroke volume index, epinephrine, 
norepinephrine, cortisol and IL-6 were log-transformed due to non-normality. Means 
included in tables and figures have been back-transformed.
For each cardiovascular or neuroendocrine measure, t-tests comparing levels during the 
baseline period versus during the speech task were used to confirm a significant effect of the 
TSST on cardiovascular and neuroendocrine measures.
Univariate regression analyses, using a p-value of 0.05 as the criterion for statistical 
significance, assessed whether hot flashes and night sweats were each associated with a 
number of potential confounding variables that have been shown to influence responses to 
mental stress. Those variables found to be significantly associated with VMS were identified 
as covariates to be included in multivariate analyses examining the association between 
VMS and cardiovascular and neuroendocrine responses to mental stress.
For each physiologic dependent measure, a multivariate repeated measures general linear 
regression model, with stress testing task (baseline, preparation, speech, arithmetic, 
recovery) as the repeated measure was used to examine the effects of hot flashes and night 
sweats (examined separately) on stress physiology. The Greenhouse-Geisser correction was 
used whenever appropriate to correct for sphericity.
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Results
Participant Characteristics
As reflected in Table 1, the participants were of average socioeconomic status and reflected 
the racial demographics of our region (73% White, 22% African American, and 5% other). 
The extent to which participants reported being bothered by hot flashes was as follows: 
33.9% endorsed “not at all”, 36.0% endorsed “a little”, 25.3% endorsed “quite a bit” and 
4.8% endorsed “extremely”. A similar distribution was seen for night sweats: 37.8% 
endorsed “not at all”, 34.6% endorsed “a little”, 22.2% endorsed “quite a bit” and 5.4% 
endorsed “extremely”.
Overall Efficacy of the Stress Protocol
Systolic blood pressure, diastolic blood pressure and heart rate all significantly increased in 
response to the mental stressors (t(179) = 32.8, 30.0 and 23.9, p<.0001, respectively) as did 
cardiac index (t(179) = 19.7, p<.0001), stroke volume index (t(180) = 2.5, p =.013), 
epinephrine (t(137) = 9.6, p<.0001), cortisol (t(169) = 8.7, p<.0001) and IL-6 (t(139) = 2.5, 
p = .013). Vascular resistance index decreased (t(179) = −8.7, p<.0001) while no effect of 
the mental stress was seen for plasma norepinephrine (p = .098) (Table 2).
Vasomotor Symptoms and Potential Confounding Variables
Neither hot flashes nor night sweats were significantly associated with race (Whites vs. 
Other, Blacks vs. Other) (ps = .150, .274), age (ps = .332, .654), household income (ps = .
492, .803), body mass index (ps = .730, .449), caffeine consumption (ps = .963, .367), 
alcohol consumption (ps = .753, .628), light physical activity (ps = .579, .622), moderate 
physical activity (ps = .547, .468), smoking (ps = .438, .655) or estradiol levels on the day of 
stress testing (ps = .651, .613). Although hot flashes were positively associated with 
postmenopausal status (relative to perimenopausal status, F(1, 185) = 8.2, p = .005), night 
sweats were not (p = .232). Hot flashes and night sweats were both positively associated 
with vigorous physical activity (β(SEM) = 0.00 (0.00), p = .006; β(SEM) = 0.00 (0.00), p = .
036) and the psychological subscale of the GCS (β(SEM) = 0.06 (0.02), p = .001; β(SEM) = 
0.09 (0.02), p <.001). Night sweats (β(SEM) = −0.14 (0.06), p = .023) but not hot flashes (p 
= .163) were also negatively associated with average number of hours of sleep. Thus, 
vigorous physical activity, postmenopausal status and psychological GCS subscale score 
were identified as appropriate covariates for multivariate analyses involving hot flashes and 
vigorous physical activity, psychological GCS subscale score while average number of hours 
of sleep were identified as appropriate covariates for multivariate analyses involving night 
sweats.
Hot Flashes and Physiologic Responses to Stress
Multivariate analyses examining the effect of hot flashes on stress physiology included 
average weekly METs of vigorous physical activity, psychological GCS subscale score and 
menopausal status as covariates.
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Blood pressure and heart rate—Hot flashes were not associated with systolic blood 
pressure (p = .715), diastolic blood pressure (p = .916) or heart rate (p = .971), nor did hot 
flashes interact with task to influence these variables (ps = .303-.610).
Hemodynamic measures—Hot flashes were associated with lower overall cardiac index 
(F(1, 170) = 7.66, p = .006) (Figure 1) and stroke volume index (F(1, 170) = 7.35, p = .007) 
and higher overall vascular resistance index (F(1, 169) = 5.72, p = .018) (Figure 2). 
However, hot flashes did not interact with task to predict cardiac index, stroke volume index 
or vascular resistance index levels (ps = .499, .528 and .759, respectively).
Norepinephrine—Hot flashes tended to be associated with overall higher norepinephrine 
(F(1, 130) = 2.80, p = .097) (Figure 3) and tended to interact with task to predict 
norepinephrine levels (F(2, 260) = 2.51, p = .097) such that the effect of hot flashes on 
norepinephrine was only significant at baseline (p = .025).
Epinephrine—Hot flashes were not associated with overall epinephrine (p = .168) and did 
not interact with task to predict epinephrine levels (p = .993).
Cortisol—Hot flashes tended to be associated with overall elevated cortisol levels (F(1, 
157) = 2.80, p = .097) (Table 3) but symptoms did not interact with task to predict cortisol 
levels (p =.395).
Interleukin-6 (IL-6)—Hot flashes were associated with overall higher IL-6 (F(1, 128) = 
4.71, p = .032) and interacted with task to predict IL-6 levels (F(1, 640) = 4.21, p = .002) 
such that the effect of hot flashes on IL-6 was significant at all time points except 45 and 60 
minutes following the end of the TSST.
Night Sweat Severity and Physiologic Responses to Stress
Multivariate analyses examining the effect of night sweats on stress reactivity included 
average number of hours of sleep per night and average weekly METs of vigorous physical 
activity and psychological GCS subscale score as covariates.
Blood pressure and heart rate—Night sweats were not associated with systolic blood 
pressure (p = .900), diastolic blood pressure (p = .510) or heart rate (p = .605), nor did night 
sweats interact with task to influence these variables (ps = .373-.608).
Hemodynamic measures—Night sweats were not associated with overall cardiac index 
or vascular resistance index (ps = .125, .123), and did not interact with task to predict 
cardiac index or vascular resistance index levels (ps = .736 and .967, respectively). No main 
effect of night sweats or any symptom-by-task interaction effect was observed for stroke 
volume index (ps = .222, .867).
Norepinephrine—Night sweats were not associated with overall norepinephrine (p = .
125) and did not interact with task to predict norepinephrine levels (p = .533).
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Epinephrine—Night sweats were not associated with overall epinephrine levels (p = .142) 
and did not interact with task to predict epinephrine levels (p = .845).
Cortisol—Night sweats were positively associated with cortisol levels overall (F(1, 153) = 
4.55, p = .035) but did not interact with task to predict cortisol levels (p = .289) (Figure 4).
Interleukin-6 (IL-6)—Night sweats tended to be associated with higher overall IL-6 levels 
(F(1, 124) = 3.36, p = .069) (Table 3) but symptoms did not interact with task to predict IL-6 
levels (p = .110).
Discussion
The current study investigated the relationship between self-reported VMS and 
physiological responses to an acute mental stressor battery. Results indicated that although 
VMS bother was not associated with alterations in stress reactivity, per se, self-reported hot 
flash bother was associated with lower overall cardiac index, lower overall stroke volume 
index, higher overall vascular resistance index and higher overall IL-6 levels. Hot flash 
bother also tended to be associated with elevated baseline norepinephrine levels and higher 
overall cortisol. Night sweat bother, on the other hand, was only associated with higher 
overall cortisol levels and tended to be associated with higher overall IL-6 levels.
Plasma norepinephrine is primarily reflective of sympathetic neural activity42 while plasma 
epinephrine primarily reflects sympathoadrenal medullary activity; the current results 
therefore suggest that hot flash bother tends to be associated with elevated sympathetic 
neural activation but unaltered sympathoadrenal activation. An increase in central versus 
peripheral ANS activity may help explain why hot flashes were found to be associated with 
overall lower cardiac index, lower stroke volume index and higher vascular resistance index. 
Plasma norepinephrine, which was higher overall in women reporting being more bothered 
by hot flashes, binds to β-adrenergic receptors on the heart, leading to increased cardiac 
output; in the vasculature, however, norepinephrine preferentially binds to α-adrenergic 
receptors, stimulation of which promotes vasoconstriction and increased vascular 
resistance43. Thus, a relative profile of increased vasoconstriction coupled with decreased 
myocardial activity is consistent with the relatively elevated plasma norepinephrine levels 
observed in women with more bothersome hot flashes.
Our finding that self-reported hot flash bother and, to a lesser extent, night sweat bother, is 
associated with elevated norepinephrine levels is consistent with the observation that 3-
methoxy-4-hydroxyphenylglcol (MHPG), the main metabolite of plasma norepinephrine, is 
significantly higher in postmenopausal women suffering from VMS compared with 
asymptomatic women44. It is also in line with several studies implicating the ANS in the 
pathophysiology of hot flashes themselves. For example, as mentioned above, there is some 
evidence that increasing central sympathetic output with the use of yohimbine (which blocks 
the α2 autoreceptor on noradrenergic neurons and therefore increases norepinephrine 
output) provokes hot flashes while inhibiting central sympathetic activation with clonidine 
(an α2 autoreceptor agonist) reduces hot flashes (see 20 for review). Studies examining 
changes in heart rate variability with hot flash onset also suggest that hot flashes are 
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associated with a shift in sympathovagal balance toward sympathetic predominance16-19. 
However, to our knowledge, the current study is the first to examine VMS in relation to 
indices of both sympathetic and sympathoadrenal medullary activation within the context of 
acute mental stress.
It is unclear why daytime hot flashes, but not night sweats, were associated with elevations 
in central sympathetic activity as well as hemodynamic alterations in cardiac output, stroke 
volume and total peripheral resistance. These differences will need to be replicated using 
objective measures of hot flash and night sweat severity to ensure that the observed 
differences are not driven by less accurate reporting of night sweats relative to daytime hot 
flashes.
Though the results of this cross-sectional study should be considered preliminary, if 
confirmed in future research, the association of hot flashes with higher vascular resistance 
index, lower cardiac index and lower stroke volume index may have important implications 
for our understanding of the relationship between VMS and CVD. Reduced myocardial 
activity and greater vasoconstriction in the context of stress is seen in individuals at higher 
risk for CVD relative to their lower risk counterparts; for example, in postmenopausal 
relative to premenopausal women 45, in men relative to premenopausal women46, 47, and in 
Blacks relative to Whites48, 49. Perhaps more relevant to the current study's finding that hot 
flash severity was associated with overall hemodynamic tone rather than hemodynamic 
stress reactivity, per say, Blacks have also been shown to have lower resting cardiac index 
and higher resting vascular resistance index compared with Whites,30 and aging (the primary 
predictor of cardiovascular disease) is associated with increases in resting vascular resistance 
index and decreases in resting cardiac index50. Moreover, greater vascular resistance index 
tone may contribute to left ventricular hypertrophy51, an independent predictor of 
cardiovascular disease morbidity/mortality52, 53.
Multivariate analyses also suggested a positive association between night sweats and, to a 
lesser extent, hot flashes, and circulating cortisol levels. These results are consistent with 
one study linking self-reported VMS bother to increased 24-hour urinary cortisol output54 as 
well as the observation that cortisol levels increase following an objectively-assessed hot 
flash21. Given that HPA axis hyperarousal is associated with multiple cardiovascular disease 
risk factors, including abdominal obesity, hypertension, insulin resistance and diabetes55, 56, 
a positive association between VMS and circulating cortisol levels could have important 
health implications for menopausal women.
Hot flash, and to a lesser extent, night sweat bother were also associated with elevated IL-6 
levels in multivariate analyses. Though few studies have examined the association between 
VMS and inflammation, one study did observe elevated IL-6 and IL-8 levels among women 
reporting more severe hot flashes57. The Study of Women's Health Across the Nation 
(SWAN) did not, however, find a relationship between VMS frequency and C-reactive 
protein58 when adjusting for body mass index, the levels of which would be expected to rise 
in response to elevated levels of IL-6 – further research is therefore needed to settle these 
inconsistencies. Though the mechanisms by which VMS would be associated with greater 
inflammation are unknown, one possibility may be that prolonged/ repeated exposure to 
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elevated cortisol, both in the context of hot flashes themselves21 and during stress (as 
suggested by the current findings) promotes a desensitization to cortisol's anti-inflammatory 
effects, a process that has been hypothesized to underlie the association between chronic 
stress and increased inflammation25.
The current study results should be interpreted in light of several limitations, perhaps the 
most important of which is its use of self-reported VMS bother using two questionnaire 
items. Assessing objective VMS frequency using skin conductance or even prospective diary 
would allow us to rule out the possibility that the HPA axis, autonomic and hemodynamic 
alterations observed in the current study are associated with a greater propensity to be 
bothered by VMS, rather than being associated with VMS themselves. A related second 
limitation is that we cannot rule out the possibility that some women reporting more 
bothersome VMS experienced a hot flash either prior to or during stress testing, which might 
have influenced some of the measures under investigation. Third, the cross-sectional nature 
of this study does not allow us to determine the direction of the relationship between VMS 
severity and the neuroendocrine and hemodynamic alterations observed. Longitudinal 
studies will clarify whether these physiologic alterations precede or are preceded by the 
development of VMS in menopause. Such research would provide some insight into whether 
the observed VMS-related hemodynamic, neuroendocrine and immune/inflammatory 
alterations are etiologically related to VMS, result from repeated exposure to VMS, or are a 
by-product of some other process influencing VMS. Fourth, hemodynamic data estimated by 
impedance cardiography are validated for research purposes only59 and are not intended to 
reflect clinical indices of cardiovascular function as determined by invasive catheter-based 
hemodynamic assessments. Hemodynamic data produced by impedance cardiography may 
also be less precise than catheter-based assessments. Finally, generalizability of the current 
study's findings may be limited by several aspects of the study design. First, the fact that the 
women were participants of a randomized clinical trial of hormone therapy disallowed the 
inclusion of women who may have been at greatest risk for menopausal symptoms for safety 
reasons (e.g., women with obesity) and also likely resulted in a sample that was healthier 
than average perimenopausal women. Second, although our sample was racially diverse, 
there was less diversity in socioeconomic status, which could well influence the nature and 
frequency of psychosocial stressors that were proximate to the menopause transition. 
Despite these limitations, the current study fills an important gap in the literature. Though 
two studies have examined whether mental stress induces VMS in the laboratory17, 60, to our 
knowledge, this is the first study to examine whether VMS bother is associated with altered 
physiologic responses to acute stress. Its comprehensive assessment of cardiovascular 
hemodynamic, catecholamine, HPA, and immune/inflammatory measures is also particularly 
unique. If confirmed in longitudinal and interventional studies, the current study's findings 
suggest potential mechanisms by which VMS may be associated with an increased risk of 
cardiovascular disease.
Conclusions
The current study suggests that self-reported VMS bother is associated with greater HPA 
and immune/inflammatory activation, both of which have been associated with an increased 
risk for cardiovascular disease and its precursors. Hot flashes are additionally associated 
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with elevated baseline central sympathetic tone, and an impedance-derived hemodynamic 
profile characterized by lower cardiac output and stroke volume and greater 
vasoconstriction, which is also associated with an increased cardiovascular disease risk. 
Should the current study's results be replicated using a state of the art measure of VMS, they 
may have important implications for understanding potential relationship between VMS and 
indices of cardiovascular disease risk and well as the physiology of VMS themselves.
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Figure 1. 
Adjusted mean impedance-derived cardiac index in women endorsing being “not at all” (n = 
58) versus “quite a bit” or “extremely” (n = 52) bothered by hot flashes. *p<.05; **p<.01
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Figure 2. 
Adjusted mean impedance-derived vascular resistance index in women endorsing being “not 
at all” (n = 58) versus “quite a bit” or “extremely” (n = 52) bothered by hot flashes. #p<.10 
*p<.05
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Figure 3. 
Adjusted mean norepinephrine in women endorsing being “not at all” (n = 48) versus “quite 
a bit” or “extremely” (n = 42) bothered by hot flashes. #p<.10
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Figure 4. 
Adjusted mean cortisol in women endorsing being “not at all” (n = 59) versus “quite a bit” 
or “extremely” (n = 46) bothered by night sweats. *p<.05; **p<.01
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Table 1
Participant characteristics (n = 186)
Mean (SD) or %
Age (yrs) 51.0 (3.1)
Gross Household Income (U.S. dollars) $50,000-79,000
BMI (kgs/m2) 25.7 (3.8)
Race
    % White 73.1%
    % African American 21.5%
    % Other 5.4%
% Postmenopausal 16.7%
% Endorsing hot flashes 66.1%
% Endorsing night sweats 62.2%
% Endorsing physical activity
    Light 88%
    Moderate 66%
    Vigorous 60%
Alcohol consumption (drinks/ week) 2.0 (1.0)
Caffeine consumption (cups/ day) 2.5 (0.9)
Smokers (%) 4.3%
Hours of sleep per night 6.9 (1.1)
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